|
[1]
|
Long, G.V., Swetter, S.M., Menzies, A.M., Gershenwald, J.E. and Scolyer, R.A. (2023) Cutaneous Melanoma. Lancet, 402, 485-502. [Google Scholar] [CrossRef]
|
|
[2]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Eddy, K., Shah, R. and Chen, S. (2020) Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. Frontiers in Oncology, 10, Article No. 626129. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Patton, E.E., Mueller, K.L., Adams, D.J., Anandasabapathy, N., Aplin, A.E., Bertolotto, C., et al. (2021) Melanoma Models for the Next Generation of Therapies. Cancer Cell, 39, 610-631. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Randic, T., Kozar, I., Margue, C., Utikal, J. and Kreis, S. (2021) NRAS Mutant Melanoma: Towards Better Therapies. Cancer Treatment Reviews, 99, Article No. 102238. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Liu, K., Hong, B., Wang, S., Lou, F., You, Y., Hu, R., et al. (2023) Pharmacological Activity of Cepharanthine. Molecules, 28. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Rogosnitzky, M., Okediji, P. and Koman, I. (2020) Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19. Pharmacological Reports, 72, 1509-1516. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Miller, A.J. and Mihm Jr., M.C. (2006) Melanoma. The New England Journal of Medicine, 355, 51-65. [Google Scholar] [CrossRef]
|
|
[9]
|
Sboner, A., Eccher, C., Blanzieri, E., Bauer, P., Cristofolini, M., Zumiani, G., et al. (2003) A Multiple Classifier System for Early Melanoma Diagnosis. Artificial Intelligence in Medicine, 27, 29-44. [Google Scholar] [CrossRef]
|
|
[10]
|
Dzwierzynski, W.W. (2013) Managing Malignant Melanoma. Plastic and Reconstructive Surgery, 132, 446e-460e. [Google Scholar] [CrossRef]
|
|
[11]
|
Eggermont, A.M.M., Blank, C.U., Mandala, M., Long, G.V., Atkinson, V., Dalle, S., et al. (2018) Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The New England Journal of Medicine, 378, 1789-1801. [Google Scholar] [CrossRef]
|
|
[12]
|
Robert, C., Grob, J.J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., et al. (2019) Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England Journal of Medicine, 381, 626-636. [Google Scholar] [CrossRef]
|
|
[13]
|
Jiang, J., Ding, Y., Wu, M., Chen, Y., Lyu, X., Lu, J., et al. (2020) Integrated Genomic Analysis Identifies a Genetic Mutation Model Predicting Response to Immune Checkpoint Inhibitors in Melanoma. Cancer Medicine, 9, 8498-8518. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Shen, L.W., Jiang, X.X., Li, Z.Q., Li, J., Wang, M., Jia, G.F., et al. (2022) Cepharanthine Sensitizes Human Triple Negative Breast Cancer Cells to Chemotherapeutic Agent Epirubicin via Inducing Cofilin Oxidation-Mediated Mitochondrial Fission and Apoptosis. Acta Pharmacologica Sinica, 43, 177-193. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Yang, Z.Y., Li, L.G., Xiong, Y.L., Chen, N.N., Yu, T.T., Li, H.T., et al. (2023) Cepharanthine Synergizes with Photodynamic Therapy for Boosting ROS-Driven DNA Damage and Suppressing MTH1 as a Potential Anti-Cancer Strategy. Photodiagnosis and Photodynamic Therapy, 45, Article No. 103917. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Su, G.F., Huang, Z.X., Huang, D.L., Chen, P.X., Wang, Y. and Wang, Y.F. (2022) Cepharanthine Hydrochloride Inhibits the Wnt/Beta‑Catenin/Hedgehog Signaling Axis in Liver Cancer. Oncology Reports, 47. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lu, Y.Y., Zhu, C.Y., Ding, Y.X., Wang, B., Zhao, S.F., Lv, J., et al. (2023) Cepharanthine, a Regulator of Keap1-Nrf2, Inhibits Gastric Cancer Growth through Oxidative Stress and Energy Metabolism Pathway. Cell Death Discovery, 9, 450. [Google Scholar] [CrossRef] [PubMed]
|